Rasagiline mesylate
Rasagiline mesylate structure
|
Common Name | Rasagiline mesylate | ||
|---|---|---|---|---|
| CAS Number | 161735-79-1 | Molecular Weight | 267.344 | |
| Density | 1.05 g/cm3 | Boiling Point | 305.5ºC at 760 mmHg | |
| Molecular Formula | C13H17NO3S | Melting Point | 155-158°C | |
| MSDS | Chinese USA | Flash Point | 146.8ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Lancet 365(9463) , 947-54, (2005) Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease. This study investigated rasagiline efficacy and safety in levodopa-treat... |
|
|
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Clin. Neuropharmacol. 23(6) , 324-30, (2000) Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monotherapy in patients with early Parkinson's disease (PD) has a... |
|
|
Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
Neuroreport 9(4) , 703-7, (1998) Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been primed with 10% serum for 12 h (p < 0.05). Rasagiline, but not d... |
|
|
Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice.
Neurobiol. Aging 36 , 2628-36, (2015) The present study aimed to investigate the protective effects of prolonged treatment with the selective, irreversible monoamine oxidase-B inhibitor, novel anti-parkinsonian drug, rasagiline (Azilect) in aged animals. Our findings from behavioral experiments d... |
|
|
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
J. Pharmacol. Exp. Ther. 356 , 483-92, (2016) According to the catecholaldehyde hypothesis, the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) contributes to the loss of nigrostriatal dopaminergic neurons in Parkinson's disease. Monoamine oxidase-A (MAO-A) catalyzes the conversion of i... |